ResearchSafe

Is the hype around PE 22-28 actually grounded?

Posted by biohacker_priya in Research & News - 5 points, 6 comments.

I was reading up on the spadin derived peptide PE 22-28 and the claims about it blocking the TREK-1 potassium channel to trigger rapid neurogenesis are pretty wild. The idea that it could produce antidepressant effects faster than SSRIs in animal models sounds promising, but I am skeptical.

Since it is still preclinical, we have basically zero human safety data to lean on. I have always been cautious about jumping on these things before we know the long term side effects, especially when it comes to messing with brain plasticity. For me, the risk of the unknown usually outweighs the potential for a quick fix.

I keep seeing it pop up in longevity and cognitive circles, but I am not convinced yet. It feels like another one of those compounds where the mouse data is extrapolated too quickly to humans... Does anyone here have actual experience with this or is it just theoretical for now? I would be curious to know if anyone has tracked their mood or cognitive function on it, or if we are all just guessing based on the /peptides/pe-22-28 info... Thanks for any insight.

Comments

  • rachel266: I have not taken PE 22‑28 myself, but a few people I know in a local biohacking group have tried it on very small, low doses. Aecdotally they report feeling a slight lift in mood after a few weeks, but they also mention mild headaches and a sense of jitteriness. I am still wary, because the compound is very new and we only have short‑term data from rodents. Until there are human safety studies, I would keep the risk–benefit ratio on the cautious side, especially for something that modulates brai
  • nate_g: tbh I can see where you’re coming from. I’ve tried a low dose of a similar peptide and did get a mild headache and a bit of a jittery feeling. How long did they wait before noticing the mood lift? It would be useful to see whether that response is consistent.
  • kyle_k: Yeah, small group anecdotes are interesting but not proof. Headaches and jitters could be from dosing or other stress, maybe? Small samples are risky, could be placebo or individual stuff. Curious if they noted when the headaches hit or if they adjusted doses. Still, human data is the gold standard here.
  • biohacker_priya: I agree, without solid human trials it’s all guesswork. I haven’t personally tried PE 22‑28, so I can’t speak to headaches or jitters myself. 5 mg instead of 1 mg. Did the thread you mentioned give any specifics on how they titrated or if they tried splitting the dose across the day? Thanks.
  • biohacker_priya: I haven’t tried PE 22‑28 yet, so I can’t give you a time‑to‑effect from my own data. I’ve only read that in a mouse model the antidepressant‑like activity peaks within a few hours of delivery, but that’s not a human reference. If you saw a mood lift, how many hours from injection until it kicked in? Also, how long(mi) did the headache and jitteriness last for you? That detail would help gauge the risk window.
  • biohacker_priya: Did the headaches linger past the mood lift, or were they temporary? Also, what dosage range were they using? Low doses might mask risks, but if even small amounts cause those symptoms, it’s worth caution. I’m still not convinced without human data.

Community discussion - research and educational context only. Not medical advice.